Theriva Biologics, Inc. (TOVX)

In October 2025, Theriva Biologics announced a warrant inducement agreement and presented data from the VIRAGE trial. November 2025 saw the report of Q3 2025 results and an updated cash runway into Q1 2027. In February 2026, SYN-020 was licensed to Rasayana Therapeutics. March 2026 included reporting full-year 2025 results, a positive FDA meeting regarding VCN-01, and Rare Pediatric Drug Designation for VCN-01, leading to a stock surge. April 2026 involved announcing an upcoming presentation of VIRAGE trial data, also causing the stock to surge, and a request for shareholder approval of warrant shares. May 2026 saw the report of Q1 2026 results, with the stock price declining by 7.09% in the two weeks leading up to May 8, 2026.

Traditional demand seasonality is not a relevant factor for Theriva Biologics, as the demand for its investigational therapies is driven by the progression of clinical trials, regulatory approvals, and the medical need for treatments in the diseases it targets.

Theriva Biologics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for cancer and related diseases with high unmet medical needs. The company is advancing an oncolytic adenovirus platform designed for various delivery methods to induce tumor cell death, enhance the penetration of co-administered cancer therapies, and stimulate an anti-tumor immune response. Its major product candidates include VCN-01, SYN-004, SYN-020, and several preclinical candidates like VCN-11, SYN-006, and SYN-007.

Theriva Biologics is headquartered in Rockville, Maryland, United States, and has operations in Spain through its subsidiary, Theriva Biologics, S.L. Clinical trials for VCN-01 are conducted in both the United States and the European Union.

Theriva Biologics' brand reputation is primarily influenced by its clinical development progress and regulatory milestones. Positive news regarding clinical trial data and FDA designations have generated positive market sentiment. Analyst ratings generally show a "Buy" consensus, indicating a favorable outlook from financial experts.

Institutional investors own a significant portion of Theriva Biologics' stock, with 23 institutions holding 1,329,794 shares as of May 7, 2026. Major institutional owners include Vanguard Group Inc., UBS Group AG, and BlackRock, Inc. The largest individual shareholder is Steven A. Shallcross, owning 250,000 shares, representing 0.54% of the company.